

AD _____

GRANT NUMBER DAMD17-97-1-7187

TITLE: The Role of Phosphotyrosine Phosphatases in Breast Cancer

PRINCIPAL INVESTIGATOR: Juliatiek Roestamadj, Ph.D.

CONTRACTING ORGANIZATION: Indiana University
Bloomington, Indiana 47402-1847

REPORT DATE: June 1999

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20000303 066

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY <i>(Leave blank)</i>	2. REPORT DATE June 1999	3. REPORT TYPE AND DATES COVERED Final (1 Jun 97 - 31 May 99)	
4. TITLE AND SUBTITLE The Role of Phosphotyrosine Phosphatases in Breast Cancer		5. FUNDING NUMBERS DAMD17-97-1-7187	
6. AUTHOR(S) Roestamadji, Juliatiek, Ph.D.		8. PERFORMING ORGANIZATION REPORT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Indiana University Bloomington, Indiana 47402-1847			
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012		10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES			
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited		12b. DISTRIBUTION CODE	
13. ABSTRACT <i>(Maximum 200 words)</i> <p style="text-align: center;">This report describes the development and synthesis and studies of a biotinylated affinity reagent of Yop51. This molecule is being used to isolate Yop51 that is present in <i>E. coli</i> cell lysate.</p>			
14. SUBJECT TERMS Breast Cancer		15. NUMBER OF PAGES 9	
		16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

___ Where copyrighted material is quoted, permission has been obtained to use such material.

___ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

~~___~~ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

___ In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

✓ ___ For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

~~___~~ In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

~~___~~ In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

~~___~~ In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

Julianek Rostamadji 6/29/99
PI - Signature Date

TABLE OF CONTENTS

Front Cover	1
SF 298 Report Documentation Page	2
Foreword	3
Table of Contents	4
Introduction	5
Body	5 - 8
Conclusions	8
Appendix	9

INTRODUCTION


The increased expression of certain phosphotyrosine phosphatases (PTPases) has been associated with oncogenic cell transformation in a number of different tissues, including breast tissue. The exact role of PTPases in transformed cells is still not yet determined, but it is likely that they play a key role in tumorigenesis. Therefore, PTPases have become a topic of interest in signal transduction research. In our laboratory, we are interested in learning more about PTPases and their possible roles in tumorigenesis. *Yersinia* PTPase (Yop51) is the enzyme we work with. It shares a significant homology to most members of PTPase enzyme family. In the previous report, the synthesis and studies of the prototypic, nonpeptidic affinity reagent for PTPases were described. Along with that on-going effort, we are in the process of developing biotinylated affinity reagents to "fish out" PTPases from cell lysate. Such molecules may potentially serve as tools to identify PTPases that are expressed in tumor cells.

BODY


Biotinylated Analog of α -Bromobenzylphosphonate (2)

We incorporated the prototype affinity reagent (compound 1) into a biotinylated analog (compound 2) as shown in the synthetic scheme 1. Compound 2 comprises of three components, the α -bromophosphonate, a linker and a biotin molecule. The ability of compound 2 to inactivate Yop51 is comparable to compound 1. Their IC₅₀ values are 1.8 mM and 1.9 mM respectively. Compound 2 was designed such that the α -bromobenzylphosphonate moiety covalently modifies Yop51. The linker would expose the biotin portion into solution. The labeled enzyme could then be probed using streptavidin-horseradish peroxidase conjugate and detected using chemiluminescent reagents.

Figure 1. Affinity Reagents for PTPases



Scheme 1. Synthetic scheme of compound 2



Labeling of Yop51

The enzyme was inactivated with a range of concentrations of compound 2. The mixtures were then loaded on to a SDS Page gel. The protein bands were subsequently transblotted on to a polyvinylidene fluoride (PVDF) microporous membrane. The membrane was treated with blocking agent (5% low fat dry milk in phosphate saline buffer) and probed with streptavidin-horseradish peroxidase conjugate. ECL Western blotting reagents were used to identify the bound streptavidine conjugate. The chemiluminescent reaction was detected by exposure to blue-light sensitive autoradiography film.

Compound 3 (Scheme 2) was prepared as a control molecule to ensure that Yop51-compound 2 adduct is formed due to the inactivation of the enzyme by the α -bromophosphonate moiety. Compound 3 is similar to compound 2 except for the absence of bromide at the α -position. It has a shorter linker than compound 2. Our preliminary studies (not shown here) indicated any linker comprised of no less than 12 atoms is able to place the biotin moiety at the surface of the protein to interact with streptavidin conjugate.

Scheme 2. Synthetic scheme of compound 3





Figure 2. Representation of labeled proteins detected on autoradiography film
 Lane 1: molecular weight marker; lane 2: 200 μg protein from *E. coli* cell lysate treated with 0.05 mM compound 2; lane 3: 1.75 μg Yop51 treated with 0.05 mM compound 2; lane 4: a mixture of 1.75 μg Yop51 and 100 μg protein from *E. coli* cell lysate treated with 0.05 mM compound 2; lane 5: 100 μg protein from *E. coli* cell lysate treated with 0.05 mM compound 3.



Within detection limits, labeled Yop51 was observed when it was treated with 0.05 mM of compound **2** at minimum. Compound **3**, on the other hand, gave no detectable protein adduct at this concentration (data not shown).

Indicated in Figure 2, treating *E. coli* cell lysate (200 µg total protein concentration) with 0.05 mM of compound **2** revealed that compound **2** labeled a large number of proteins (lane 2). We are interested to determine the nature of modification of those proteins by compound **2**. Labeled Yop51 (1.75 µg total protein concentration) gave a single band (lane 3). Treating a mixture of 100 µg *E. coli* cell lysate and 1.75 µg Yop51 with 0.05 mM of compound **2** gave a number of labeled proteins (lane 4). Unfortunately it is not clear whether Yop51 was labeled or not since its band coincides with an *E. coli* protein of similar molecular weight.

CONCLUSION

Our effort to develop a biotinylated affinity reagent that can be used to isolate PTPases in tumor cells has resulted in the synthesis and studies of compound **2**. It inactivates Yop51 in low millimolar range and the labeled protein can be detected by probing the biotin moiety with streptavidin-horseradish peroxidase conjugate. Further studies are being carried out to identify labeled Yop51 in the presence of other proteins present in cell extract.

APPENDIX

Key Research Accomplishments

- * Synthesis and studies of non-peptidic inactivators of Yop51
- * Synthesis and studies of biotinylated affinity reagent of Yop51
- * Isolation and detection of Yop51 labeled with the biotinylated affinity reagent